Market Summary
USD205.14-0.06
Market Closed-0.03%
LH Alerts
LH Stock Price
LH RSI Chart
LH Valuation
LH Price/Sales (Trailing)
LH Profitability
LH Fundamentals
LH Revenue
LH Earnings
Price Action
52 Week Range
198.69258.90
(Low)(High)
Last 7 days
0.3%
Last 30 days
-4.8%
Last 90 days
-12.6%
Trailing 12 Months
-6.5%
LH Financial Health
LH Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for LH
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-08-08 | ANDERSON KERRII B | sold | -1,057,830 | 211 | -5,000 | - |
2023-08-01 | Wilkinson Peter J | sold (taxes) | -3,631 | 213 | -17.00 | svp, chief accounting officer |
2023-08-01 | Wilkinson Peter J | acquired | - | - | 56.00 | svp, chief accounting officer |
2023-06-29 | van der Vaart Sandra D | sold | -50,880 | 240 | -212 | evp, chief legal officer |
2023-05-19 | Kirchgraber Paul R | sold | -932,707 | 216 | -4,300 | ceo, covance drug development |
2023-05-19 | Kirchgraber Paul R | acquired | 784,793 | 182 | 4,300 | ceo, covance drug development |
2023-05-18 | Schroeder Mark S | acquired | 195,900 | 130 | 1,500 | evp, pres diagnostics & coo |
2023-05-18 | Schroeder Mark S | sold | -325,155 | 216 | -1,500 | evp, pres diagnostics & coo |
2023-03-31 | Schroeder Mark S | sold | -879,982 | 225 | -3,897 | evp, president-diagnostics lab |
2023-03-30 | Wilkinson Peter J | acquired | - | - | 1,798 | svp, chief accounting officer |
Which funds bought or sold LH recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-20 | Mondrian Investment Partners LTD | added | 5.92 | 16,211,300 | 158,182,000 | 3.16% |
2023-09-18 | WASHINGTON CAPITAL MANAGEMENT, INC | added | 113 | 672,340 | 1,211,480 | 1.03% |
2023-09-12 | Farther Finance Advisors, LLC | added | 31.5 | 22,355 | 80,638 | 0.02% |
2023-09-08 | TUCKER ASSET MANAGEMENT LLC | reduced | -74.19 | -5,181 | 1,931 | -% |
2023-09-07 | JAG CAPITAL MANAGEMENT, LLC | added | 36.7 | 760,562 | 2,497,040 | 0.29% |
2023-09-07 | ST GERMAIN D J CO INC | new | - | 43,439 | 43,439 | -% |
2023-09-05 | Covenant Partners, LLC | unchanged | - | 14,030 | 284,287 | 0.10% |
2023-08-25 | EUBEL BRADY & SUTTMAN ASSET MANAGEMENT INC | added | 2.18 | 1,015,000 | 14,568,000 | 2.01% |
2023-08-24 | Alberta Investment Management Corp | added | 33.68 | 177,080 | 612,978 | 0.01% |
2023-08-23 | Rehmann Capital Advisory Group | reduced | -0.47 | 57,198 | 1,278,620 | 0.12% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
LH Alerts
Schedule 13G FIlings of Laboratory Corporation of America Holdin
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 09, 2023 | vanguard group inc | 11.79% | 10,450,115 | SC 13G/A | |
| Jan 26, 2023 | blackrock inc. | 13.0% | 11,474,507 | SC 13G/A | |
| Jan 20, 2023 | blackrock inc. | 13.0% | 11,474,507 | SC 13G/A | |
| Mar 09, 2022 | blackrock inc. | 10.4% | 9,706,541 | SC 13G/A | |
| Feb 10, 2022 | vanguard group inc | 11.24% | 10,753,065 | SC 13G/A | |
| Feb 01, 2022 | blackrock inc. | 8.6% | 8,274,411 | SC 13G/A | |
| Feb 10, 2021 | vanguard group inc | 10.68% | 10,405,602 | SC 13G/A | |
| Jan 29, 2021 | blackrock inc. | 8.0% | 7,832,565 | SC 13G/A | |
| Feb 12, 2020 | vanguard group inc | 11.21% | 10,891,852 | SC 13G/A | |
| Feb 05, 2020 | blackrock inc. | 9.1% | 8,855,703 | SC 13G/A |
Recent SEC filings of Laboratory Corporation of America Holdin
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Sep 14, 2023 | 8-K | Current Report | |
| Sep 11, 2023 | 8-K | Current Report | |
| Aug 10, 2023 | 4 | Insider Trading | |
| Aug 09, 2023 | 8-K | Current Report | |
| Aug 08, 2023 | 144 | Notice of Insider Sale Intent | |
| Aug 04, 2023 | 10-Q | Quarterly Report | |
| Aug 03, 2023 | 4 | Insider Trading | |
| Jul 31, 2023 | 8-K | Current Report | |
| Jul 27, 2023 | 8-K | Current Report | |
| Jul 24, 2023 | SC 13D/A | 13D - Major Acquisition |
LH Fair Value
Loading...
Peers (Alternatives to Laboratory Corporation of America Holdin)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
HCA | 69.4B | 61.9B | -7.50% | 26.00% | 12.02 | 1.12 | 3.02% | -11.37% |
LH | 18.2B | 14.1B | -4.84% | -6.54% | 21.91 | 1.29 | -5.68% | -58.27% |
DGX | 14.0B | 9.5B | -5.93% | 1.08% | 17.63 | 1.48 | -10.34% | -46.50% |
| MID-CAP | ||||||||
DVA | 9.4B | 11.7B | 1.41% | 13.03% | 20.16 | 0.8 | 0.96% | -43.93% |
CHE | 7.8B | 2.2B | 2.63% | 10.06% | 34.39 | 3.56 | 2.13% | -18.31% |
THC | 7.1B | 19.9B | -2.85% | 22.41% | 6.26 | 0.36 | 3.98% | -22.32% |
EHC | 7.0B | 4.6B | -0.06% | 39.84% | 22.16 | 1.52 | 9.56% | -4.24% |
ACHC | 6.5B | 2.8B | -6.23% | -13.68% | 23.9 | 2.33 | 13.40% | -2.45% |
PGNY | 3.3B | 957.5M | -8.01% | -15.46% | 66.71 | 3.43 | 55.17% | 8.05% |
GH | 3.2B | 510.2M | -27.36% | -50.73% | -6.35 | 6.32 | 25.00% | 4.56% |
| SMALL-CAP | ||||||||
RDNT | 1.9B | 1.5B | -8.12% | 43.46% | -147.16 | 1.24 | 12.20% | -155.34% |
XGN | 39.3M | 52.9M | -8.98% | -46.92% | -1.12 | 0.74 | 23.27% | 10.26% |
AMS | 15.5M | 20.4M | -11.49% | -6.52% | 28.15 | 0.76 | 9.05% | -51.79% |
OTRK | 4.7M | 10.8M | -41.82% | -73.41% | -0.13 | 0.43 | -71.53% | 35.85% |
Laboratory Corporation of America Holdin News
Returns for LH
Cumulative Returns on LH
7.6%
10-Year Cumulative Returns
6.1%
7-Year Cumulative Returns
3.8%
5-Year Cumulative Returns
4.1%
3-Year Cumulative Returns
Risks for LH
What is the probability of a big loss on LH?
66.5%
Probability that Laboratory Corporation of America Holdin stock will be more than 20% underwater in next one year
37.7%
Probability that Laboratory Corporation of America Holdin stock will be more than 30% underwater in next one year.
19.2%
Probability that Laboratory Corporation of America Holdin stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does LH drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Laboratory Corporation of America Holdin was unfortunately bought at previous high price.
Drawdowns
Financials for Laboratory Corporation of America Holdin
Income Statement (Last 12 Months)(In Millions)
| Income Statement (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Revenue | 0.8% | 14,092 | 13,981 | 14,877 | 14,485 | 14,941 | 15,859 | 16,121 | 16,555 | 16,388 | 15,316 | 13,979 | 12,442 | 11,475 | 11,587 | 11,555 | 11,389 | 11,292 | 11,276 | 11,333 | 11,291 | 11,081 |
| Cost Of Revenue | 2.1% | 10,246 | 10,035 | 10,492 | 9,875 | 10,005 | 10,601 | 10,497 | 10,400 | 10,060 | 9,492 | 9,026 | 8,574 | 8,348 | 8,397 | 8,302 | 8,185 | 8,115 | 8,089 | 8,157 | 8,070 | 7,865 |
| Gross Profit | -2.5% | 3,846 | 3,947 | 4,385 | 4,610 | 4,936 | 5,258 | 5,624 | 6,154 | 6,328 | 5,824 | 4,953 | 3,869 | 3,127 | 3,191 | 3,253 | 3,204 | 3,177 | 3,187 | 3,176 | 3,221 | 3,215 |
| S&GA Expenses | 3.6% | 2,106 | 2,033 | 1,997 | 1,950 | 1,960 | 1,986 | 1,952 | 1,926 | 1,826 | 1,764 | 1,729 | 1,625 | 1,607 | 1,626 | 1,625 | 1,608 | 1,588 | 1,568 | 1,571 | 1,591 | 1,591 |
| Interest Expenses | 4.0% | 196 | 189 | 180 | 174 | 170 | 206 | 212 | 217 | 227 | 201 | 207 | 224 | 233 | 239 | 241 | 235 | 233 | 237 | 244 | 254 | 254 |
| Net Income | -17.0% | 831 | 1,000 | 1,279 | 1,756 | 1,991 | 2,099 | 2,377 | 2,763 | 2,879 | 2,643 | 1,556 | 845 | -175 | -216 | 286 | 217 | 853 | 896 | 884 | 1,414 | 1,266 |
| Net Income Margin | -100.0% | - | 0.07* | 0.09* | 0.12* | 0.13* | 0.13* | 0.15* | 0.17* | 0.18* | 0.17* | 0.11* | 0.07* | 0.03* | 0.03* | 0.07* | - | - | - | - | - | - |
| Free Cashflow | -100.0% | - | 1,263 | 1,474 | 1,486 | 1,865 | 1,704 | 2,777 | 2,777 | 2,836 | 2,719 | 1,754 | 1,520 | 1,174 | 1,070 | 1,045 | - | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Assets | -12.3% | 17,719 | 20,200 | 20,155 | 19,826 | 20,403 | 20,728 | 20,385 | 20,867 | 20,417 | 20,417 | 20,072 | 18,740 | 17,849 | 17,298 | 18,046 | 17,848 | 17,744 | 16,971 | 16,185 | 16,661 | 16,505 |
| Current Assets | 9.1% | 5,121 | 4,695 | 4,625 | 4,372 | 5,031 | 5,230 | 5,331 | 6,021 | 5,694 | 5,638 | 5,125 | 4,086 | 3,413 | 2,891 | 2,981 | 2,988 | 2,849 | 2,885 | 2,835 | 3,274 | 3,021 |
| Cash Equivalents | 390.1% | 1,931 | 394 | 321 | 410 | 978 | 1,234 | 1,473 | 2,037 | 1,963 | 1,891 | 1,321 | 667 | 557 | 324 | 338 | 361 | 265 | 349 | 427 | 893 | 893 |
| Inventory | 1.3% | 488 | 481 | 471 | 468 | 436 | 441 | 401 | 411 | 421 | 428 | 423 | 393 | 342 | 254 | 245 | 235 | 220 | 234 | 237 | 233 | 231 |
| Net PPE | -6.2% | 2,762 | 2,944 | 2,794 | 2,885 | 2,870 | 2,808 | 2,815 | 2,692 | 2,702 | 2,697 | 2,730 | 2,609 | 2,628 | 2,610 | 2,637 | 2,463 | 2,544 | 2,458 | 1,740 | 1,734 | 1,711 |
| Goodwill | -23.8% | 6,182 | 8,116 | 6,124 | 8,218 | 8,114 | 8,166 | 7,959 | 7,907 | 7,745 | 7,721 | 7,752 | 7,614 | 7,423 | 7,389 | 7,865 | 7,815 | 7,844 | 7,386 | 7,360 | 7,363 | 7,423 |
| Liabilities | -9.4% | 8,914 | 9,839 | 10,040 | 9,715 | 9,982 | 9,987 | 10,091 | 10,321 | 10,151 | 10,375 | 10,614 | 10,481 | 10,477 | 10,260 | 10,459 | 10,597 | 10,580 | 9,840 | 9,195 | 9,393 | 9,447 |
| Current Liabilities | -24.3% | 2,183 | 2,886 | 3,079 | 2,522 | 2,643 | 2,642 | 2,783 | 2,888 | 2,667 | 3,369 | 3,079 | 3,010 | 3,034 | 2,458 | 2,656 | 2,555 | 2,496 | 2,527 | 1,879 | 2,106 | 2,122 |
| LT Debt, Non Current | -0.2% | 5,042 | 5,052 | 5,039 | 5,334 | 5,360 | 5,383 | 5,417 | 5,417 | 5,423 | 4,921 | 5,419 | 5,417 | 5,417 | 5,790 | 5,790 | 6,101 | 6,135 | 5,496 | 5,991 | 6,045 | 6,039 |
| Shareholder's Equity | -15.1% | 8,785 | 10,342 | 10,097 | 10,092 | 10,401 | 10,721 | 10,273 | 10,601 | 10,322 | 10,098 | 9,437 | 8,239 | 7,353 | 7,020 | 7,644 | 7,020 | 7,144 | 7,111 | 7,048 | 7,248 | 7,038 |
| Retained Earnings | -17.6% | 8,836 | 10,730 | 10,582 | 10,845 | 10,898 | 10,948 | 10,457 | 10,787 | 10,417 | 10,172 | 9,479 | 8,464 | 7,761 | 7,529 | 7,981 | 7,677 | 7,456 | 7,265 | 7,157 | 6,922 | 6,603 |
| Additional Paid-In Capital | 97.9% | 94.00 | 48.00 | - | - | - | 29.00 | - | - | - | 67.00 | 110 | 81.00 | 32.00 | - | 27.00 | 48.00 | 91.00 | 1,401 | 1,451 | 1,828 | 1,935 |
| Shares Outstanding | -13.9% | 89.00 | 103 | 88.00 | 104 | 106 | 111 | 108 | 111 | 112 | 114 | 113 | 113 | 113 | 113 | 113 | 113 | 114 | 115 | 115 | 118 | 119 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | -12.8% | 1,500 | 1,721 | 1,956 | 2,000 | 2,393 | 2,308 | 3,110 | 3,187 | 3,206 | 3,089 | 2,135 | 1,931 | 1,600 | 1,483 | 1,445 | 1,361 | 1,158 | 1,292 | 1,305 | 1,384 | 1,529 |
| Share Based Compensation | 0.8% | 148 | 147 | 144 | 156 | 165 | 163 | 154 | 138 | 107 | 123 | 112 | 108 | 113 | 99.00 | 107 | 104 | 92.00 | 91.00 | 92.00 | 95.00 | 109 |
| Cashflow From Investing | -0.9% | -1,189 | -1,178 | -1,652 | -1,633 | -1,477 | -1,325 | -884 | -758 | -636 | -669 | -643 | -667 | -621 | -1,249 | -1,283 | -1,277 | -488 | 141 | 207 | 175 | -1,688 |
| Cashflow From Financing | 148.3% | 660 | -1,365 | -1,322 | -1,958 | -1,787 | -1,633 | -2,065 | -1,058 | -1,173 | -864 | -517 | -965 | -684 | -252 | -252 | -606 | -620 | -1,428 | -1,389 | -1,067 | 80.00 |
| Dividend Payments | -1.1% | 259 | 261 | - | 175 | 89.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Buy Backs | - | 2,200 | - | 1,100 | 1,600 | 933 | 800 | - | 669 | 437 | 137 | 100 | 219 | 250 | 450 | 450 | 800 | 850 | 725 | 700 | 340 | 232 |
LH Income Statement
2023-06-30CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| Net restructuring and other special charges | $ 15.8 | $ 31.5 | $ 23.3 | $ 35.0 |
| Operating Income (Loss) | 266.3 | 428.8 | 596.1 | 1,034.0 |
| Interest Expense | 49.8 | 42.3 | 100.5 | 84.4 |
| Equity method income, net | 0.9 | 1.4 | (1.2) | 4.8 |
| Investment income | 4.5 | 1.7 | 6.7 | 2.5 |
| Other, net | (16.9) | (29.5) | (23.8) | (45.2) |
| Earnings before income taxes | 205.0 | 360.1 | 477.3 | 911.7 |
| Provision for income taxes | 49.8 | 92.1 | 113.7 | 222.6 |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest | 155.2 | 268.0 | 363.6 | 689.1 |
| Net earnings | 189.1 | 358.9 | 402.4 | 851.0 |
| Net Income (Loss) Attributable to Noncontrolling Interest | 0.2 | 0.3 | 0.6 | 0.8 |
| Net Income (Loss) Attributable to Parent | $ 188.9 | $ 358.6 | $ 401.8 | $ 850.2 |
| Income (Loss) from Continuing Operations, Per Basic Share | $ 1.75 | $ 2.90 | $ 4.10 | $ 7.43 |
| Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share | 0.38 | 0.99 | 0.43 | 1.74 |
| Basic earnings per common share (in dollars per share) | 2.13 | 3.89 | 4.53 | 9.17 |
| Diluted earnings per common share (in dollars per share) | $ 2.12 | $ 3.87 | $ 4.51 | $ 9.11 |
| Revenues | $ 3,033.7 | $ 2,923.0 | $ 6,071.5 | $ 6,067.5 |
| Cost of Revenue | 2,191.5 | 1,980.5 | 4,379.2 | 4,042.9 |
| Gross Profit | 842.2 | 942.5 | 1,692.3 | 2,024.6 |
| Selling, general and administrative expenses | 505.8 | 432.4 | 963.0 | 854.4 |
| Amortization of intangibles and other assets | 51.5 | 49.8 | 104.9 | 100.0 |
| Asset Impairment Charges | 2.8 | 0.0 | 5.0 | 1.2 |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest | $ 33.9 | $ 90.9 | $ 38.8 | $ 161.9 |
| Income (Loss) from Continuing Operations, Per Diluted Share | $ 1.74 | $ 2.89 | $ 4.08 | $ 7.38 |
| Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share | $ 0.38 | $ 0.98 | $ 0.43 | $ 1.73 |
| Revenues | $ 3,033.7 | $ 2,923.0 | $ 6,071.5 | $ 6,067.5 |
| Cost of Revenue | 2,191.5 | 1,980.5 | 4,379.2 | 4,042.9 |
| Gross Profit | 842.2 | 942.5 | 1,692.3 | 2,024.6 |
| Selling, general and administrative expenses | 505.8 | 432.4 | 963.0 | 854.4 |
| Amortization of intangibles and other assets | 51.5 | 49.8 | 104.9 | 100.0 |
| Asset Impairment Charges | 2.8 | 0.0 | 5.0 | 1.2 |
| Net restructuring and other special charges | 15.8 | 31.5 | 23.3 | 35.0 |
| Operating Income (Loss) | 266.3 | 428.8 | 596.1 | 1,034.0 |
| Other income (expenses): | ||||
| Interest expense | (49.8) | (42.3) | (100.5) | (84.4) |
| Equity method income, net | 0.9 | 1.4 | (1.2) | 4.8 |
| Investment income | 4.5 | 1.7 | 6.7 | 2.5 |
| Other, net | (16.9) | (29.5) | (23.8) | (45.2) |
| Earnings before income taxes | 205.0 | 360.1 | 477.3 | 911.7 |
| Provision for income taxes | 49.8 | 92.1 | 113.7 | 222.6 |
| Net earnings | 189.1 | 358.9 | 402.4 | 851.0 |
| Less: Net earnings attributable to the noncontrolling interest | (0.2) | (0.3) | (0.6) | (0.8) |
| Net earnings attributable to Laboratory Corporation of America Holdings | $ 188.9 | $ 358.6 | $ 401.8 | $ 850.2 |
| Basic earnings per common share (in dollars per share) | $ 2.13 | $ 3.89 | $ 4.53 | $ 9.17 |
| Diluted earnings per common share (in dollars per share) | $ 2.12 | $ 3.87 | $ 4.51 | $ 9.11 |
LH Balance Sheet
2023-06-30CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) | 3 Months Ended | 6 Months Ended | |
|---|---|---|---|
Jun. 30, 2023 USD ($) | Jun. 30, 2023 USD ($) | Dec. 31, 2022 USD ($) | |
| Current assets: | |||
| Accounts Receivable, after Allowance for Credit Loss, Current | $ 1,904,800,000 | $ 1,904,800,000 | $ 1,785,500,000 |
| Unbilled Contracts Receivable | 137,800,000 | 137,800,000 | 211,800,000 |
| Supplies inventories | 487,800,000 | 487,800,000 | 470,600,000 |
| Prepaid expenses and other | 659,900,000 | 659,900,000 | 610,400,000 |
| Disposal Group, Including Discontinued Operation, Assets, Current | 0 | 0 | 1,226,100,000 |
| Total current assets | 5,120,900,000 | 5,120,900,000 | 4,625,000,000 |
| Property, plant and equipment, net | 2,762,100,000 | 2,762,100,000 | 2,794,100,000 |
| Goodwill, net | 6,182,200,000 | 6,182,200,000 | 6,123,700,000 |
| Intangible Assets, Net (Excluding Goodwill) | 3,154,100,000 | 3,154,100,000 | 3,123,600,000 |
| Joint venture partnerships and equity method investments | 67,200,000 | 67,200,000 | 65,700,000 |
| Deferred Income Taxes and Other Assets, Current | 6,400,000 | 6,400,000 | 6,400,000 |
| Other assets, net | 425,800,000 | 425,800,000 | 378,400,000 |
| Disposal Group, Including Discontinued Operation, Assets, Noncurrent | 0 | 0 | 3,038,200,000 |
| Total assets | 17,718,700,000 | 17,718,700,000 | 20,155,100,000 |
| Liabilities, Current [Abstract] | |||
| Accounts Payable, Current | 713,100,000 | 713,100,000 | 852,200,000 |
| Accrued Liabilities, Current | 657,800,000 | 657,800,000 | 787,000,000.0 |
| Deferred Revenue, Current | 349,700,000 | 349,700,000 | 310,600,000 |
| Operating Lease, Liability, Current | 154,800,000 | 154,800,000 | 163,800,000 |
| Finance Lease, Liability, Current | 6,500,000 | 6,500,000 | 6,000,000.0 |
| Current debt excluding finance lease liability | 301,400,000 | 301,400,000 | 301,300,000 |
| Long-term debt, less current portion | 2,183,300,000 | 2,183,300,000 | 3,078,500,000 |
| Long-term Debt, Excluding Current Maturities | 5,042,400,000 | 5,042,400,000 | 5,038,800,000 |
| Commitments and contingent liabilities | 418,500,000 | 418,500,000 | 401,100,000 |
| Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent | 0 | 0 | 241,300,000 |
| Operating Lease, Liability, Noncurrent | 623,500,000 | 623,500,000 | 652,900,000 |
| Finance Lease, Liability, Noncurrent | 81,700,000 | 81,700,000 | 83,600,000 |
| Deferred income taxes and other tax liabilities | 564,500,000 | 564,500,000 | 543,400,000 |
| Noncontrolling interest | 8,913,900,000 | 8,913,900,000 | 10,039,600,000 |
| Shareholders' equity: | |||
| Common stock, 92.8 and 93.5 shares outstanding at March 31, 2013 and December 31, 2012, respectively | 19,800,000 | 19,800,000 | 18,900,000 |
| Additional paid-in capital | 94,400,000 | 94,400,000 | 0 |
| Retained earnings | 8,100,000 | 8,100,000 | 8,100,000 |
| Accumulated other comprehensive income | (8,836,200,000) | (8,836,200,000) | (10,581,700,000) |
| Total liabilities and shareholders' equity | (153,700,000) | (153,700,000) | (493,200,000) |
| Stockholders' Equity Attributable to Parent | 8,785,000,000 | 8,785,000,000 | 10,096,600,000 |
| Liabilities and Equity | 17,718,700,000 | 17,718,700,000 | 20,155,100,000 |
| Net earnings | 189,100,000 | 402,400,000 | |
| Cash and cash equivalents | 1,930,600,000 | 1,930,600,000 | 320,600,000 |
| Disposal Group, Including Discontinued Operation, Liabilities, Current | $ 0 | $ 0 | $ 657,600,000 |
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, and parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. It provides online and mobile applications to enable patients to check test results; and online applications for managed care organizations. It offers end-to-end drug development, medical device, and diagnostic development solutions from early-stage research to clinical development and commercial market access. It serves managed care organizations, biopharmaceutical companies, physicians and other healthcare providers, hospitals and health systems, governmental agencies, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, and independent clinical laboratories. The company was founded in 1971 and is headquartered in Burlington, North Carolina.